Tag: Laevoroc's

Laevoroc’s LR 09 is given orphan medication classification by the US FDA to treat leukaemia relapse following allogeneic stem cell transplant.

LR 09, a novel metabolic immune checkpoint inhibitor, has been given Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of patients with haematological malignancies who have been identified with a relapse following allogeneic stem…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram